Sagimet Biosciences
SGMT | NASDAQ
$10.13
-$0.09 (-0.88%)
At close: Nov 16, 2026, 4:00 PM ET
$10.33
+$0.20 (+1.97%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Sagimet Biosciences Company Profile
Company profile explainedCompany Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President & Director |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer |
| Andreas Grauer | Chief Medical Officer |
| Elizabeth Rozek | Chief Legal & Administrative Officer |
| Lucas Pelkmans | Co-Founder |
| Marie O'Farrell | Chief Scientific Officer |
| Robert D'Urso | Senior Vice President of New Products |
| Urs Greber | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 01, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 424B5 | Filing |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 424B3 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 4 | Filing |
Sagimet Biosciences
| Country | United States |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | David Happel |
Contact Details
155 Bovet Road San Mateo,
California 94402 United States
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove SGMT